HS
KALV

HighVista Strategies’s KalVista Pharmaceuticals KALV Stock Holding History

HighVista Strategies’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-33,305
Closed -$384K – 162
2025
Q1 		$384K Hold
33,305
– – 0.15% 133
2024
Q4 		$282K Hold
33,305
– – 0.1% 137
2024
Q3 		$386K Buy
33,305
+1,432
+4% +$18K 0.13% 140
2024
Q2 		$375K Hold
31,873
– – 0.14% 122
2024
Q1 		$378K Buy
+31,873
New +$425K 0.13% 130
2023
Q3 		– Sell
-69,567
Closed -$626K – 151
2023
Q2 		$626K Buy
+69,567
New +$641K 0.29% 111

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

HighVista Strategies's KALV Position: Q2 2025 in Review

HighVista Strategies sold out of KalVista Pharmaceuticals (KALV) in Q2 2025, closing a stake of 33,305 shares — an estimated $384K sold.

HighVista Strategies first reported a position in KALV in Q2 2023 and held it in 6 quarters. The position peaked at $626K in Q2 2023. 139 funds tracked by Wall St. Rank hold KALV as of Q2 2025.

  • HighVista Strategies reported no remaining KalVista Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • HighVista Strategies sold 33,305 KalVista Pharmaceuticals shares in Q2 2025, an estimated $384K.
  • HighVista Strategies first reported a position in KalVista Pharmaceuticals in Q2 2023 and held it in 6 quarters.
  • HighVista Strategies's KalVista Pharmaceuticals position peaked at $626K in Q2 2023.
  • 139 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2025.

Based on HighVista Strategies's 13F filing for Q2 2025, filed 14 Aug 2025.